Top entities: Alladapt Immunotherapeutics, Bernstein Liebhard LLP, Peter Allocco, United States — United States District Court for the Northern District of California.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory class action

MoonLake Immunotherapeutics faces class action

Q: When did this event occur?

First reported Oct 16, 2025; last updated Nov 24, 2025.

Q: What is the market impact?

General. The class action lawsuit against Alladapt Immunotherapeutics could lead to a decline in its stock price due to investor concerns about alleged misrepresentations regarding its drug candidate.

Analysis based on 6 articles · First reported Oct 16, 2025 · Last updated Nov 24, 2025

Sentiment

-20

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit against Alladapt Immunotherapeutics could lead to a decline in its stock price due to investor concerns about alleged misrepresentations regarding its drug candidate. This event highlights the risks associated with investing in biotechnology companies and the importance of accurate drug candidate promotion.

Biotechnology Legal Services

Event Summary

Bernstein Liebhard LLP has filed a securities fraud class action lawsuit against Alladapt Immunotherapeutics in the United States — United States District Court for the Northern District of California. The lawsuit alleges that Alladapt Immunotherapeutics and its senior officers made misrepresentations concerning its drug candidate, sonelokimab (SLK), promoting it as superior to competing monoclonal antibody drugs. Investors who purchased Alladapt Immunotherapeutics common stock between March 10, 2024, and September 29, 2025, are encouraged to join the class action, with a lead plaintiff deadline of December 15, 2025. Peter Allocco is the Investor Relations Manager for Bernstein Liebhard LLP.

Entities Involved

priv

Alladapt Immunotherapeutics

Alladapt Immunotherapeutics is facing a securities fraud class action lawsuit for allegedly making misrepresentations about its drug candidate, sonelokimab (SLK), which could negatively impact its stock price and reputation.

Importance 100.0 Sentiment -50.0

priv

Bernstein Liebhard LLP

Bernstein Liebhard LLP is the law firm that filed the securities class action lawsuit against Alladapt Immunotherapeutics, representing investors who allegedly lost money.

Importance 80.0 Sentiment 20.0

per

Peter Allocco

Peter Allocco is the Investor Relations Manager at Bernstein Liebhard LLP and serves as a contact for investors interested in joining the class action lawsuit.

Importance 10.0 Sentiment 0.0

govactor

United States — United States District Court for the Northern District of California

Importance 0.0 Sentiment 0.0

Relationships

Bernstein Liebhard LLP related ↔ Peter Allocco

Bernstein Liebhard LLP related ↔ United States — United States District Court for the Northern District of California

Peter Allocco related ↔ United States — United States District Court for the Northern District of California

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard